Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Earnings

Corporate emblem and logo of Neuphoria Therapeutics, Inc. (NEUP)

This price chart for Neuphoria Therapeutics Inc. (NEUP) illustrates the performance of the company developing therapies for CNS and anxiety disorders, where the PE ratio stands at -1.00. Financial stability is underpinned by support from global corporations during testing, which minimizes costs. However, patent disputes in neurology create risks of investment loss. Capital intensity is decreasing as research is outsourced to external contractors, eliminating operational disruptions.

Neuphoria (NEUP): Price to Earnings Ratio from 12/25/2024 to 11/17/2026

Analytical breakdowns for Neuphoria Therapeutics Inc.

Comprehensive company analysis:Neuphoria Therapeutics - NEUP
Flagship merchandise of Neuphoria Therapeutics

Neuphoria Therapeutics Inc. (NEUP) high R&D expenditures and the uncertainty surrounding clinical trial timelines render traditional earnings valuations secondary. The P/E ratio measures the market value of the business relative to its net income, reflecting the balance between growth expectations and current efficiency. Analyzing the company's P/E level allows for the distinction between an undervalued asset and a stagnating business, where a low multiple signals frozen capital.

Key competitors

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Assertio Therapeutics (ASRT)|Business Payback Period Coya|Vistagen - Price to Earnings Ratio|Company Value to Net Income OVID|Acumen Pharmaceuticals Inc. - P/E Multiple|Market Cap to Earnings CervoMed Inc|ATHE: P/E Multiple|Price to Earnings Ratio Clene Nanomedicine|Price to Earnings Ratio PepGen Corp|Jupiter Neurosciences (JUNS) - Business Payback Period|Price to Earnings Ratio Relmada Therapeutics, Inc. (RLMD)|ANVS - Market Cap to Earnings|gracetx.com - Price to Earnings Ratio|AIFF: Price to Earnings Multiple|Klotho Neurosciences - P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Earnings Multiple|Reviva Pharmaceuticals (RVPH) - Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|Price to Earnings Ratio NeurAxis, Inc|Price to Earnings Ratio HSDT|P/E Multiple PASG|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple